Want to see IN:SAKAR full AI Analyst Report?
SAKAR Stock Chart & Stats
₹802.20
₹27.80(3.47%)
At close: 4:00 PM EDT
₹802.20
₹27.80(3.47%)
Day’s Range― - ―
52-Week Range₹352.00 - ₹1,229.85
Previous CloseN/A
Volume110.03K
Average Volume (3M)114.14K
Market Cap
₹19.53B
Enterprise Value₹24.78B
Total Cash (Recent Filing)₹2.60M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)45.8
Beta0.62
Next Earnings
Feb 08, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)16.23
Shares Outstanding21,949,910
10 Day Avg. Volume134,066
30 Day Avg. Volume114,135
Financial Highlights & Ratios
PEG Ratio0.52
Price to Book (P/B)3.42
Price to Sales (P/S)4.41
P/FCF Ratio100.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue GrowthAccelerating revenue indicates stronger demand and expanding commercial reach across Sakar’s formulation portfolio. If sustained, this growth can increase operating scale, support reinvestment in products and markets, and provide a durable foundation for improving earnings over the next several quarters.
Meaningful DeleveragingThe sharp reduction in leverage materially lowers balance-sheet risk and interest-related pressure. A more conservative capital structure gives Sakar greater flexibility to fund operations, pursue growth opportunities, and withstand fluctuations in pharmaceutical demand without relying as heavily on borrowing.
Diversified Formulation PlatformA broad finished-dosage portfolio spanning multiple dosage forms, therapeutic segments, and geographies provides several avenues for revenue generation. This breadth can reduce reliance on one product category or market and supports the company’s ability to build scale across domestic and export channels.
Bears Say
Weak Cash-flow ConversionAlthough cash generation has improved, the low conversion of reported earnings into free cash flow raises questions about the durability and quality of profit realization. Persistently modest conversion could constrain internally funded expansion and make working-capital discipline increasingly important.
Margin VolatilityThe substantial decline in gross margin suggests that profitability has become more sensitive to product mix, pricing, or cost conditions. Even with solid current net margins, continued volatility could limit earnings predictability and reduce the operating benefit of future revenue growth.
Moderate Shareholder ReturnsImproving ROE is encouraging, but its still-moderate level indicates that the company is not yet generating especially strong returns on its equity base. This may limit the efficiency of retained capital and places greater importance on sustaining growth and improving profitability.
Sakar Healthcare Ltd News
SAKAR FAQ
What was Sakar Healthcare Ltd’s price range in the past 12 months?
Sakar Healthcare Ltd lowest stock price was ₹352.00 and its highest was ₹1229.85 in the past 12 months.
What is Sakar Healthcare Ltd’s market cap?
Sakar Healthcare Ltd’s market cap is ₹19.53B.
When is Sakar Healthcare Ltd’s upcoming earnings report date?
Sakar Healthcare Ltd’s upcoming earnings report date is Feb 08, 2027 which is in 106 days.
How were Sakar Healthcare Ltd’s earnings last quarter?
Sakar Healthcare Ltd released its earnings results on Oct 22, 2026. The company reported ₹5.082 earnings per share for the quarter.
Is Sakar Healthcare Ltd overvalued?
According to Wall Street analysts Sakar Healthcare Ltd’s price is currently Overvalued.
Does Sakar Healthcare Ltd pay dividends?
Sakar Healthcare Ltd does not currently pay dividends.
What is Sakar Healthcare Ltd’s EPS estimate?
Sakar Healthcare Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sakar Healthcare Ltd have?
Sakar Healthcare Ltd has 21,949,910 shares outstanding.
What happened to Sakar Healthcare Ltd’s price movement after its last earnings report?
Sakar Healthcare Ltd reported an EPS of ₹5.082 in its last earnings report. Following the earnings report the stock price went up 5.195%.
Which hedge fund is a major shareholder of Sakar Healthcare Ltd?
Currently, no hedge funds are holding shares in IN:SAKAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sakar Healthcare Ltd
Sakar Healthcare Limited, founded in 2004 and based in Ahmedabad, India, is a pharmaceutical company actively involved in the full spectrum of drug development, from research and manufacturing to marketing its products. The company's diverse product line includes liquid oral medications, cephalosporin-based drugs (available as tablets, capsules, and dry powder syrups), various injectable forms such as dry powder injections, and liquid injectable solutions (supplied in ampoules, vials, and lyophilized preparations), alongside oral solid dosages. Their comprehensive portfolio addresses approximately 22 distinct therapeutic categories, encompassing treatments for conditions like acidity, malaria, blood clotting, constipation, respiratory issues, pain, infections, depression, allergies, and nutritional deficiencies, among others. Sakar Healthcare also has a significant global reach, distributing its products to roughly 38 countries across regions including Southeast Asia, other parts of Asia, both English and French-speaking African nations, the Middle East and North Africa, and the United States.
Technical Analysis
Ind-Swift Laboratories Ltd.
―
Jagsonpal Pharmaceuticals Ltd.
―
Lincoln Pharmaceuticals Ltd
―
Syncom Formulation (India) Ltd.
―
Venus Remedies Limited
―